Evidence map›Paper›PMID 41228275›Full record

ArticleCancers2025

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years.

María Victoria Mateos, Evangelos Terpos, Sara Martínez, Carmen Kahatt, Javier Jiménez, Sonia Extremera, Javier Gómez, Vicente Alfaro, Heinz Ludwig

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

María Victoria MateosDepartment of Hematology, University Hospital of Salamanca/IBSAL, 37007 Salamanca, Spain.ORCID 0000-0003-2390-1218
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-5133-1422
Sara MartínezClinical R&D, PharmaMar, Colmenar Viejo, 28770 Madrid, Spain.
Carmen KahattClinical R&D, PharmaMar, Colmenar Viejo, 28770 Madrid, Spain.
Javier JiménezClinical R&D, PharmaMar, Colmenar Viejo, 28770 Madrid, Spain.
Sonia ExtremeraClinical R&D, PharmaMar, Colmenar Viejo, 28770 Madrid, Spain.
Javier GómezClinical R&D, PharmaMar, Colmenar Viejo, 28770 Madrid, Spain.
Vicente AlfaroClinical R&D, PharmaMar, Colmenar Viejo, 28770 Madrid, Spain.ORCID 0000-0002-0150-2390
Heinz LudwigWilhelminen Cancer Research Institute, Department of Medicine, Center for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, 1160 Vienna, Austria.

Funding

The study was funded by PharmaMar S.A. APL-C-001-09
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

dexamethasonemultiple myelomaoverall survivalplitidepsinprogression-free survival

Identifiers

PMID41228275
PMCPMC12608838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.